# Comparative Pharmacokinetics and Safety of Cannabidiol in a Powder Formulation, CBtru > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cbd-powder-formulation-pharmacokinetics-study/ > **Published:** 2026-04-27T02:19:23-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:54:37-04:00 > **Clinical Summary:** Explore the CBD powder formulation pharmacokinetics study showing comparable bioavailability to oil-based products with unique absorption profiles. --- CED Clinical Relevance  #100High Clinical Relevance Evidence Brief | CED ClinicNovel powder CBD formulation demonstrates comparable bioavailability to oil-based products with improved fasting absorption in healthy adults. CbdPharmacokineticsFormulationBioavailabilityRct Novel powder CBD formulation demonstrates comparable bioavailability to oil-based products with improved fasting absorption in healthy adults. What This Study Teaches Us This crossover study demonstrates that powder-based CBD formulations can achieve bioavailability comparable to established oil-based products. The distinct pharmacokinetic profiles under fasted versus fed conditions suggest formulation affects absorption patterns beyond simple bioequivalence. Why This Matters Oil-based CBD formulations can be challenging for patients due to taste, storage requirements, and dosing variability. A powder formulation with comparable bioavailability could improve patient adherence and provide more consistent dosing, particularly important for conditions requiring precise CBD levels. Study Snapshot Study Type Phase I Randomized Crossover Trial Population Healthy adults, sample size not specified in abstract Intervention Single 400mg dose of encapsulated powdered emulsion CBD (CBtru) Comparator Oil-based CBD formulation Primary Outcome Pharmacokinetic profile and bioavailability Key Finding CBtru showed comparable bioavailability with distinct PK profiles under fasted and fed conditions Journal CNS Drugs Year 2024 Clinical Bottom Line Powder CBD formulations may offer a viable alternative to oil-based products with similar therapeutic potential. The improved fasting absorption could provide more predictable dosing for patients who cannot or prefer not to take CBD with food. What This Paper Does Not Show This study does not demonstrate clinical efficacy for any medical condition, long-term safety, or how these pharmacokinetic differences translate to therapeutic outcomes. No patient populations with actual medical conditions were studied. Where This Paper Deserves Skepticism The study was conducted only in healthy adults, limiting generalizability to patients with medical conditions who metabolize drugs differently. Sample size is not reported, and single-dose studies may not reflect steady-state kinetics relevant to chronic dosing. Dr. Caplan's Take This is encouraging formulation science that could improve [patient experience](https://cedclinic.com/testimonials/), but I need to see clinical efficacy data before changing prescribing patterns. The real question is whether these pharmacokinetic differences translate to better therapeutic outcomes or fewer [side effects](https://cedclinic.com/cannabis-intoxication-memory-disruption/) in actual patients. What a Careful Reader Should Take Away Powder CBD formulations show promise for achieving reliable absorption comparable to oils. However, this pharmacokinetic study alone cannot guide clinical decision-making without corresponding efficacy and safety data in relevant patient populations. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Comparative%20Pharmacokinetics%20and%20Safety%20of%20Cannabidiol%20in%20a%20Powder%20Formulation%2C%20CBtru%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2Fcbd-powder-formulation-pharmacokinetics-bioavailability-study%2F)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcbd-powder-formulation-pharmacokinetics-bioavailability-study%2F)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Comparative%20Pharmacokinetics%20and%20Safety%20of%20Cannabidiol%20in%20a%20Powder%20Formulation%2C%20CBtru%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2Fcbd-powder-formulation-pharmacokinetics-bioavailability-study%2F)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Table of Contents - [FAQ](#FAQ)[How does the powder CBD formulation (CBtru) compare to traditional oil-based CBD products?](#How_does_the_powder_CBD_formulation_CBtru_compare_to_traditional_oil-based_CBD_products) - [Should CBD be taken with or without food for optimal absorption?](#Should_CBD_be_taken_with_or_without_food_for_optimal_absorption) - [What is the clinical significance of improved fasting absorption with powder CBD?](#What_is_the_clinical_significance_of_improved_fasting_absorption_with_powder_CBD) - [Is the 400-mg dose of CBD used in this study clinically relevant?](#Is_the_400-mg_dose_of_CBD_used_in_this_study_clinically_relevant) - [What are the safety implications of this powder CBD formulation for clinical practice?](#What_are_the_safety_implications_of_this_powder_CBD_formulation_for_clinical_practice) - [Related](#Related) ## FAQ #### How does the powder CBD formulation (CBtru) compare to traditional oil-based CBD products? CBtru demonstrated comparable bioavailability to oil-based CBD formulations while offering improved absorption under fasted conditions. This powder formulation provides a viable alternative to oil-based products, potentially offering more consistent dosing and better patient tolerance. #### Should CBD be taken with or without food for optimal absorption? Both CBtru and oil-based CBD formulations showed distinct pharmacokinetic profiles under fasted versus fed conditions. The study indicates that food intake significantly affects CBD absorption, though specific recommendations would depend on the formulation and therapeutic goals. #### What is the clinical significance of improved fasting absorption with powder CBD? Enhanced absorption under fasted conditions allows for more predictable dosing and may improve patient compliance by reducing the need to coordinate CBD administration with meals. This could be particularly beneficial for patients requiring precise dosing schedules or those with dietary restrictions. #### Is the 400-mg dose of CBD used in this study clinically relevant? The 400-mg dose represents a clinically meaningful dose that falls within therapeutic ranges used for various neurological, pain, and psychiatric conditions. This dose level allows for assessment of pharmacokinetic profiles that would be relevant for real-world clinical applications. #### What are the safety implications of this powder CBD formulation for clinical practice? The study demonstrated that CBtru was well-tolerated in healthy adults at a 400-mg dose, with safety profiles comparable to established oil-based formulations. This supports the potential clinical utility of powder formulations as a safe alternative delivery method for therapeutic CBD. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Cannabinoids in Pediatric Medicine: Evidence-Based Care and Emerging Research](https://cedclinic.com/cannabinoids-pediatric-clinical-evidence-review/) Explore emerging research on cannabinoids in pediatric care, focusing on evidence-based applications and safety considerations. [Read More](https://cedclinic.com/cannabinoids-pediatric-clinical-evidence-review/) [Cannabinoid Clinical Trials for Mental Disorders](https://cedclinic.com/cannabinoid-clinical-trials-mental-disorders-efficacy/) Review [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) investigating cannabinoids for [mental health disorders](https://cedclinic.com/cannabinoid-receptor-type-2-schizophrenia/), highlighting current evidence and future directions. [Explore Trials](https://cedclinic.com/cannabinoid-clinical-trials-mental-disorders-efficacy/) [The effects of cannabidiol on sleep disturbances within a sample of high trait worriers: A double-blind, randomized placebo controlled trial.](https://cedclinic.com/cbd-sleep-placebo-trial-results/) Examine [clinical trial results](https://cedclinic.com/cannabidiol-liver-enzyme-elevation-healthy-adults/) on cannabidiol's impact on sleep disturbances, providing insights into efficacy and limitations. [Learn More](https://cedclinic.com/cbd-sleep-placebo-trial-results/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).